Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma

Sang Hoon Lee, Seung Up Kim, Jeong Won Jang, Si Hyun Bae, Sanghun Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang Hyub Han

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background/purpose: Liver stiffness (LS) measurement using transient elastography can accurately assess the degree of liver fibrosis, which is associated with the risk of the development of hepatocellular carcinoma (HCC). We investigated whether LS values could predict HCC de novo recurrence after radiofrequency ablation (RFA).

Methods: This retrospective, multicenter study analyzed 111 patients with HCC who underwent RFA and LS measurement using transient elastography between May 2005 and April 2011. All patients were followed until March 2013 to monitor for HCC recurrence.

Results: This study included 76 men and 35 women with a mean age of 62.4 years, and the mean LS value was 21.2 kPa. During the follow-up period (median 22.4 months), 47 (42.3%) patients experienced HCC de novo recurrence, and 18 (16.2%) died. Patients with recurrence had significantly more frequent liver cirrhosis, more frequent history of previous treatment for HCC, higher total bilirubin, larger spleen size, larger total tumor size, higher tumor number, higher LS values, and lower platelet counts than those without recurrence (all P<0.05). On multivariate analysis, together with previous anti-HCC treatment history, patients with LS values >13.0 kPa were at significantly greater risk for recurrence after RFA, with a hazard ratio (HR) of 3.115 (95% confidence interval [CI], 1.238–7.842, P<0.05). Moreover, LS values independently predicted the mortality after RFA, with a HR of 9.834 (95% CI, 1.148–84.211, P<0.05), together with total bilirubin.

Conclusions: Our data suggest that LS measurement is a useful predictor of HCC de novo recurrence and overall survival after RFA.

Original languageEnglish
Pages (from-to)347-356
Number of pages10
JournalOncoTargets and Therapy
Volume8
DOIs
Publication statusPublished - 2015 Feb 2

Fingerprint

Elasticity Imaging Techniques
Hepatocellular Carcinoma
Recurrence
Liver
Bilirubin
Liver Cirrhosis
Confidence Intervals
Platelet Count
Multicenter Studies
Neoplasms
Spleen
Retrospective Studies
Survival
Mortality

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)

Cite this

@article{9f2b120e5e484539905a44af1bb7958e,
title = "Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma",
abstract = "Background/purpose: Liver stiffness (LS) measurement using transient elastography can accurately assess the degree of liver fibrosis, which is associated with the risk of the development of hepatocellular carcinoma (HCC). We investigated whether LS values could predict HCC de novo recurrence after radiofrequency ablation (RFA).Methods: This retrospective, multicenter study analyzed 111 patients with HCC who underwent RFA and LS measurement using transient elastography between May 2005 and April 2011. All patients were followed until March 2013 to monitor for HCC recurrence.Results: This study included 76 men and 35 women with a mean age of 62.4 years, and the mean LS value was 21.2 kPa. During the follow-up period (median 22.4 months), 47 (42.3{\%}) patients experienced HCC de novo recurrence, and 18 (16.2{\%}) died. Patients with recurrence had significantly more frequent liver cirrhosis, more frequent history of previous treatment for HCC, higher total bilirubin, larger spleen size, larger total tumor size, higher tumor number, higher LS values, and lower platelet counts than those without recurrence (all P<0.05). On multivariate analysis, together with previous anti-HCC treatment history, patients with LS values >13.0 kPa were at significantly greater risk for recurrence after RFA, with a hazard ratio (HR) of 3.115 (95{\%} confidence interval [CI], 1.238–7.842, P<0.05). Moreover, LS values independently predicted the mortality after RFA, with a HR of 9.834 (95{\%} CI, 1.148–84.211, P<0.05), together with total bilirubin.Conclusions: Our data suggest that LS measurement is a useful predictor of HCC de novo recurrence and overall survival after RFA.",
author = "Lee, {Sang Hoon} and Kim, {Seung Up} and Jang, {Jeong Won} and Bae, {Si Hyun} and Sanghun Lee and Kim, {Beom Kyung} and Park, {Jun Yong} and Kim, {Do Young} and Ahn, {Sang Hoon} and Han, {Kwang Hyub}",
year = "2015",
month = "2",
day = "2",
doi = "10.2147/OTT.S75077",
language = "English",
volume = "8",
pages = "347--356",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma. / Lee, Sang Hoon; Kim, Seung Up; Jang, Jeong Won; Bae, Si Hyun; Lee, Sanghun; Kim, Beom Kyung; Park, Jun Yong; Kim, Do Young; Ahn, Sang Hoon; Han, Kwang Hyub.

In: OncoTargets and Therapy, Vol. 8, 02.02.2015, p. 347-356.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma

AU - Lee, Sang Hoon

AU - Kim, Seung Up

AU - Jang, Jeong Won

AU - Bae, Si Hyun

AU - Lee, Sanghun

AU - Kim, Beom Kyung

AU - Park, Jun Yong

AU - Kim, Do Young

AU - Ahn, Sang Hoon

AU - Han, Kwang Hyub

PY - 2015/2/2

Y1 - 2015/2/2

N2 - Background/purpose: Liver stiffness (LS) measurement using transient elastography can accurately assess the degree of liver fibrosis, which is associated with the risk of the development of hepatocellular carcinoma (HCC). We investigated whether LS values could predict HCC de novo recurrence after radiofrequency ablation (RFA).Methods: This retrospective, multicenter study analyzed 111 patients with HCC who underwent RFA and LS measurement using transient elastography between May 2005 and April 2011. All patients were followed until March 2013 to monitor for HCC recurrence.Results: This study included 76 men and 35 women with a mean age of 62.4 years, and the mean LS value was 21.2 kPa. During the follow-up period (median 22.4 months), 47 (42.3%) patients experienced HCC de novo recurrence, and 18 (16.2%) died. Patients with recurrence had significantly more frequent liver cirrhosis, more frequent history of previous treatment for HCC, higher total bilirubin, larger spleen size, larger total tumor size, higher tumor number, higher LS values, and lower platelet counts than those without recurrence (all P<0.05). On multivariate analysis, together with previous anti-HCC treatment history, patients with LS values >13.0 kPa were at significantly greater risk for recurrence after RFA, with a hazard ratio (HR) of 3.115 (95% confidence interval [CI], 1.238–7.842, P<0.05). Moreover, LS values independently predicted the mortality after RFA, with a HR of 9.834 (95% CI, 1.148–84.211, P<0.05), together with total bilirubin.Conclusions: Our data suggest that LS measurement is a useful predictor of HCC de novo recurrence and overall survival after RFA.

AB - Background/purpose: Liver stiffness (LS) measurement using transient elastography can accurately assess the degree of liver fibrosis, which is associated with the risk of the development of hepatocellular carcinoma (HCC). We investigated whether LS values could predict HCC de novo recurrence after radiofrequency ablation (RFA).Methods: This retrospective, multicenter study analyzed 111 patients with HCC who underwent RFA and LS measurement using transient elastography between May 2005 and April 2011. All patients were followed until March 2013 to monitor for HCC recurrence.Results: This study included 76 men and 35 women with a mean age of 62.4 years, and the mean LS value was 21.2 kPa. During the follow-up period (median 22.4 months), 47 (42.3%) patients experienced HCC de novo recurrence, and 18 (16.2%) died. Patients with recurrence had significantly more frequent liver cirrhosis, more frequent history of previous treatment for HCC, higher total bilirubin, larger spleen size, larger total tumor size, higher tumor number, higher LS values, and lower platelet counts than those without recurrence (all P<0.05). On multivariate analysis, together with previous anti-HCC treatment history, patients with LS values >13.0 kPa were at significantly greater risk for recurrence after RFA, with a hazard ratio (HR) of 3.115 (95% confidence interval [CI], 1.238–7.842, P<0.05). Moreover, LS values independently predicted the mortality after RFA, with a HR of 9.834 (95% CI, 1.148–84.211, P<0.05), together with total bilirubin.Conclusions: Our data suggest that LS measurement is a useful predictor of HCC de novo recurrence and overall survival after RFA.

UR - http://www.scopus.com/inward/record.url?scp=84961379692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961379692&partnerID=8YFLogxK

U2 - 10.2147/OTT.S75077

DO - 10.2147/OTT.S75077

M3 - Article

AN - SCOPUS:84961379692

VL - 8

SP - 347

EP - 356

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -